Literature DB >> 6717376

A virus antigen (HBsAg) indicates metastases of human carcinoma cells in the nude mouse.

O Marquardt, A Freytag von Loringhoven, R Koshy, P H Hofschneider, K Miller, J Desmyter.   

Abstract

The human hepatoma cell line PLC/PRF/5 produces tumours and lung metastases in nude athymic mice. Here we describe how detection of hepatitis B virus surface antigen, a marker of these cells, as led to identification of pancreatic and muscle metastases. The antigen was shown in the tissues, and antigen-producing PLC/PRF/5 cells were isolated from them. The number of cells detectable by this method is between 5 and 10 million. The principle used here may be adaptable be useful in studying micrometastasis formation in other systems.

Entities:  

Mesh：

Substances：

Year:  1984        PMID： 6717376     DOI： 10.1007/bf02123718

Source DB:  PubMed          Journal:  Med Microbiol Immunol        ISSN： 0300-8584            Impact factor:   3.402


  10 in total

1.  Tumorigenicity and interferon properties of the PLC/PRF/5 human hepatoma cell line.

Authors:  J Desmyter; G De Groote; M B Ray; A F Bradburne; V Desmet; P De Somer; J Alexander
Journal:  Prog Med Virol       Date:  1981

2.  Expression of the hepatitis B virus surface, core and E antigen genes by stable rat and mouse cell lines.

Authors:  N M Gough; K Murray
Journal:  J Mol Biol       Date:  1982-11-25       Impact factor: 5.469

3.  Labeling of hepatitis B virus surface antigen (HBsAg) synthesized in a HBsAg-producing hepatoma cell line.

Authors:  P H Hofschneider; V Zaslavsky; F Deinhardt; G G Frösner; J J Alexander
Journal:  J Med Virol       Date:  1979       Impact factor: 2.327

4.  A human hepatoma cell line (PCL/PRF/5) produces lung metastases and secretes HBsAg in nude mice.

Authors:  F R Sattler; S Paolucci; J W Kreider; R L Ladda
Journal:  Eur J Cancer Clin Oncol       Date:  1982-04

5.  Establishment of a continuously growing cell line from primary carcinoma of the liver.

Authors:  J J Alexander; E M Bey; E W Geddes; G Lecatsas
Journal:  S Afr Med J       Date:  1976-12-18

6.  Excretion of hepatitis B surface antigen particles from mouse cells transformed with cloned viral DNA.

Authors:  M F Dubois; C Pourcel; S Rousset; C Chany; P Tiollais
Journal:  Proc Natl Acad Sci U S A       Date:  1980-08       Impact factor: 11.205

7.  Integration of hepatitis B virus DNA: evidence for integration in the single-stranded gap.

Authors:  R Koshy; S Koch; A F von Loringhoven; R Kahmann; K Murray; P H Hofschneider
Journal:  Cell       Date:  1983-08       Impact factor: 41.582

8.  Tumorigenicity in nude mice of a human hepatoma cell line containing hepatitis B virus DNA.

Authors:  D Shouval; L M Reid; P R Chakraborty; N Ruiz-Opazo; R Morecki; M A Gerber; S N Thung; D A Shafritz
Journal:  Cancer Res       Date:  1981-04       Impact factor: 12.701

9.  Recombinant retroviral DNA yielding high expression of hepatitis B surface antigen.

Authors:  C Stratowa; J Doehmer; Y Wang; P H Hofschneider
Journal:  EMBO J       Date:  1982       Impact factor: 11.598

10.  Hepatitis-B surface antigen in tumour tissue and non-tumorous liver in black patients with hepatocellular carcinoma.

Authors:  M C Kew; M B Ray; V J Desmet; J Desmyter
Journal:  Br J Cancer       Date:  1980-03       Impact factor: 7.640
  10 in total
  3 in total

Review 1.  Hepatitis B virus components produced by the human hepatoma cell line PLC/PRF/5: do they indicate virus propagation? Brief review.

Authors:  O Marquardt
Journal:  Arch Virol       Date:  1986       Impact factor: 2.574

2.  Cell type specific expression of pre S 1 antigen and secretion of hepatitis B virus surface antigen. Brief Report.

Authors:  O Marquardt; K H Heermann; M Seifer; W H Gerlich
Journal:  Arch Virol       Date:  1987       Impact factor: 2.574

3.  Cytokeratin immunohistochemically detected nodal micrometastases in N0 laryngeal cancer: impact on the overall occult metastases.

Authors:  Hesham Negm; Mohamed Mosleh; Hesham Fathy; Amal Hareedy; Ahmad Elbattawy
Journal:  Eur Arch Otorhinolaryngol       Date:  2012-07-05       Impact factor: 2.503
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.